Join to View Full Profile
1500 East Medical Center Dr3rd Floor Taubman Center Recp DAnn Arbor, MI 48109
Phone+1 734-936-5899
Fax+1 734-615-2156
Dr. Miceli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Corewell Health (Dearborn)Residency, Internal Medicine, 2009 - 2012
University of New Mexico School of MedicineFellowship, Infectious Disease, 2007 - 2009
University of Buenos AiresClass of 1992
Certifications & Licensure
MI State Medical License 2009 - 2028
NM State Medical License 2007 - 2009
American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Publications & Presentations
PubMed
- 8 citationsOlorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.Johan A Maertens, George R Thompson 3rd, Andrej Spec, Fariba M Donovan, Sarah P Hammond
The Lancet. Infectious Diseases. 2025-11-01 - Characteristics and Outcomes of Hospitalized Patients with Histoplasmosis: Comparison of Immunocompromised and Non-Immunocompromised Adult Patients.Liam M Dalton, Carol A Kauffman, Marisa H Miceli
Journal of Fungi. 2025-09-12 - Lack of Association BetweenUrine Antigen Values and Clinical Response in Persons Without HIV.Marisa H Miceli, Liam M Dalton, Alessandro C Pasqualotto, Carol A Kauffman
Open Forum Infectious Diseases. 2025-08-01
Press Mentions
Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. Mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMIDApril 18th, 2023- Patient with Candida Krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical ResolutionOctober 12th, 2023
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 23rd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
